About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Abbott Claims DOJ Let 12 Years' of Drug Pricing Documents Get Destroyed

By Jim Edwards | Jun 9, 2009

Abbott Labs has accused the Department of Justice of failing to preserve 12 years’ worth of evidence in a massive case about whether drug companies artificially inflated the price of drugs. Abbott’s motion states:

DOJ kept the lawsuit under seal for more than eleven years, conducting one-sided discovery against Abbott, but did nothing to preserve evidence in its own possession or control.

Not a single litigation hold order was issued. Not a single agency was told to preserve evidence.

The case has been dragging through federal Judge Patti Saris‘ (pictured) Massachusetts court for years. It is unbelievably complicated, but can be summed up as follows: The DOJ alleges that many drug companies offered their drugs to doctors and hospitals at prices lower than the “Average Wholesale Price” used by Medicare and Medicaid to reimburse them. The doctors would buy the drugs from the companies at the lower rate and then be reimbursed by the government at the higher rate. This situation allegedly put docs in the position of receiving cash kickbacks for using certain drugs, and caused taxpayers to be overcharged for drugs used. AWP pricing has since been outlawed.

The crux of the case comes down to the difference between prices offered and prices paid, information which is recorded by government bodies such as Medicare and Medicaid. and Abbott is clearly livid that for more than a decade, the DOJ didn’t ask those agencies to hold onto their records:

The Department of Justice (“DOJ”) waited twelve years to direct anyone to preserve
evidence relevant to this litigation.

Worse, government officials became cynical about the litigation and learned to destroy documents before they got to lawyers:

… a 2006 email from a New York pharmacy official to his colleagues in other states:

Jerry: NY has been involved in AWP litigation issues- (I can’t say how many)
through our Attorney General Office. . . . Lesson learned: get rid of any papers
that are from before state record keeping requirements – lawyers want
everything available (note: do not get rid of anything once litigation has begun or
after lawyers tell you to keep what is available – you could get in a lot of trouble).

Abbott wants damages eliminated on claims where there is no data. Among the missing data are every single email from the Centers for Medicare & Medicaid Services prior to September 2005:

In September 2005, CMS changed its email program, but made no effort to retain relevant emails. The result was a massive destruction of potentially relevant emails, even as CMS purported to respond to a subpoena.

And witnesses can’t remember what happened years ago without those records, Abbott claims:

CMS official Larry Reed agreed that it was “fair to say that you can’t tell me one way or the other whether you knew in 1993 that state Medicaid programs were using excess payments of ingredient costs to subsidize insufficient dispensing fees,” …

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • US launches probe into credit derivatives

    Financial Times - 130 days 4 hours 15 minutes ago

    The Department of Justice has opened an investigation into the credit derivatives market, with letters sent to over a dozen dealers asking for several years worth of detailed information about trading and pricing. The move comes as the regulatory spotlight continues to shine on the credit default swaps (CDS) market, a sector of the...

  • Twitter users paying for popularity

    news.com.au - 142 days 17 hours 43 minutes ago

    There's no need to panic - there's nothing wrong with you. Those that matter really do care about your commute. Just rest easy in the knowledge that all the others are just buying their friends. Yes, just as it was with other social networking sites such as StumbleUpon and Digg, web traffic and promotion company uSocial.net says it has had a...

  • Abbott joins the federal-probe parade

    FiercePharma - 12 days 3 hours 34 minutes ago

    Abbott Laboratories is the latest drugmaker to find itself in the feds' sights. Officials are probing Abbott's marketing of the epilepsy-and-mood drug Depakote, examining whether the company violated the False Claims Act and anti-kickback rules. The U.S. attorney in the Western District of Virginia is heading up the probe, but the Justice...

  • Court Suggests Abbott Lawyer Cheated on Hytrin Patent

    BNET Pharma - 298 days 20 hours 19 minutes ago

    A federal appeals court has strongly suggested that an "Abbott in-house attorney" is a cheat. In a ruling on whether Abbott Labs broke antitrust law in consipiring with generic makers to keep Hytrin, a hypertension and prostate enlargement drug, off the market, the judges described why they were sending the  case back to court for a jury trial....

  • Abbott under kickback probe over Depakote sales -

    PharmaGossip - 15 days 1 hour 29 minutes ago

    Abbott Laboratories this morning confirmed the company's sales and marketing practices of Depakote, the widely used drug to treat bipolar disorder and epilepsy, are under federal investigation. The U.S. Department of Justice , through the U.S. Attorney for the Western District of Virginia , is handling the probe, the company said in a...

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here